Group 1 - Meidi Technology plans to acquire 100% equity of Haisholi and INNOWAVE VIETNAM for a total of 2 billion KRW, which is approximately 219.47 million USD, allowing direct entry into Samsung's supply chain [3] - Toxin Pharmaceutical will increase its investment in Jiangsu Jinsan Biotechnology by 10 million CNY, acquiring a 1.75% stake, as Jinsan has successfully produced high-purity ergot sulfur [4] - Zhejiang Energy Power reported a power generation of 78.848 billion kWh in the first half of the year, a year-on-year increase of 4.48%, attributed to increased electricity demand in Zhejiang province [5] Group 2 - Tiande Yu expects a net profit of 152 million CNY for the first half of 2025, a year-on-year increase of 50.89%, driven by the growth in high-refresh-rate mobile display driver chips [7] - Pinming Technology anticipates a net profit increase of 231.79% to 302.89% for the first half of 2025, due to growth in building information software revenue and effective cost control [8] - *ST Jinglun expects a loss of 19 to 22 million CNY in the first half of 2025, despite a 23.5% increase in revenue to approximately 83 million CNY, as overall gross profit is insufficient to cover expenses [9] Group 3 - Jindi Co. signed an industrial project investment contract with the government of Bishan District, with a total investment of no less than 1.5 billion CNY [11] - Baiyun Electric is expected to win a procurement project from the State Grid worth 164 million CNY, which represents 3.28% of the company's audited revenue for 2024 [13] Group 4 - Fulei New Materials' shareholder plans to reduce its stake by up to 1.33%, amounting to a maximum of 3.7625 million shares [15] - Wind God Co. plans to raise no more than 1.1 billion CNY through a private placement for a project aimed at enhancing the capacity and efficiency of high-performance giant engineering tires [17]

天德钰：上半年净利润12.08亿元 同比增长43.35% 7月16日晚，天德钰（688252）发布2025年半年度业绩快报，公司上半年实现营业收入12.08亿元，同比 增长43.35%；实现归属于上市公司股东的净利润1.52亿元，同比增长50.89%。 资料显示，天德钰成立于2010年11月，主营业务是移动智能终端领域的整合型单芯片研发、设计、销 售。 所属行业：电子–半导体–数字芯片设计 福莱新材：股东拟减持不超过1.33%公司股份 7月16日晚，福莱新材（605488）发布公告称，股东嘉兴市进取企业管理合伙企业（有限合伙）计划通 过集中竞价及大宗交易方式减持不超过376.25万股公司股份，占公司总股本的1.33%。减持期间为2025 年8月7日至2025年11月6日。减持原因系股东个人资金需求。 资料显示，福莱新材成立于2009年6月，主营业务是功能性涂布复合材料的研发、生产、销售。 所属行业：基础化工–塑料–膜材料 金帝股份：签订不低于15亿元工业项目投资合同 7月16日晚，金帝股份（603270）发布公告称，公司拟使用自有或自筹资金向海南金海慧投资有限公司 增资，增资完成后，由金海慧在重庆设立子公司博 ...

拓新药业：拟对仅三生物增资1000万元 仅三生物实现了高纯度麦角硫因的制备 智通财经7月16日电，拓新药业(301089.SZ)公告称，公司将以自有资金1000万元对江苏仅三生物科技有 限公司（简称"仅三生物"）进行增资。本次交易完成后，公司将直接持有仅三生物1.75%的股权。仅三 生物成功实现了高纯度麦角硫因的制备，其主要产品包括麦角硫因护肤品、口服胶囊、洗眼液等。 ...

拓新药业集团股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议通知于 2025 年 7 月 12 日以电话、邮件等方式向各位董事发出，会议于 2025 年 7 月 15 日以现场会议结合通讯形式在公司会议室召开。本次会议由公司董事 长杨西宁先生召集并主持，实际出席会议的董事 9 人，其中以通讯形式出席会 议的董事 2 人，分别为咸生林、王秀强，公司监事及其他高级管理人员列席了 会议。 本次会议的召集、召开及表决符合《中华人民共和国公司法》及《拓新药 业集团股份有限公司章程》（以下简称《公司章程》）的有关规定，会议合法 有效。 二、董事会会议审议情况 1、审议通过《关于对外投资的议案》 证券代码：301089 证券简称：拓新药业 公告编号：2025-033 表决结果：9 票赞成，0 票反对，0 票弃权。 三、备查文件 1、《拓新药业集团股份有限公司第五届董事会第六次会议决议》 1 特此公告。 拓新药业集团股份有限公司 董事会 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-034 拓新药业集团股份有限公司 关于对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、对外投资概述 拓新药业集团股份有限公司（以下简称"公司"或"拓新药业"）在 2025 年 7 月 15 日召开第五届董事会第六次会议，会议审议通过了《关于对外投资的 议案》，公司将以自有资金 1,000 万元人民币对江苏仅三生物科技有限公司（以 下简称"仅三生物"或"目标公司"）进行增资，其中 22.3377 万元计入注册资 本，剩余部分计入资本公积。公司与仅三生物签署《关于江苏仅三生物科技有限 公司之增资协议》（以下简称"《增资协议》"），本次交易完成后，拓新药业 将直接持有仅三生物 1.75%的股权（最终以市场监督管理部门变更登记为准）。 二 、审议程序履行情况 公司于 2025 年 7 月 15 日召开的第五届董事会第六次会议审议通过了《关于 对外投资的议案》。根据《深圳证券交易所创业板股票上市规则》《公司章程》 等相关规定，本次对外投资事项在公司董事会决策权限范围内，无需提交公司股 ...

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

【导读】医药股盘初拉升， PCB 概念股持续火热 中国基金报记者 晨曦 大家好！来一起关注最新的市场行情和资讯 ~ 7 月 8 日， A 股三大指数开盘涨跌不一，上证指数高开 0.04% ，深证成指、创业板指飘 绿。盘初市场拉升上行，截至发稿，三大指数集体飘红，创业板指涨超 1% 。 | 3480.61 | ﻳ | 10510.71 | [ | 2154.84 | | --- | --- | --- | --- | --- | | 上证指数 +0.22% | | 深证成指 +0.72% | | 创业板指 +1.16% | 盘面上，上午电子、建材、通信、计算机等板块涨幅居前，电路板、 CRO 、消费电子代工等 概念股走高；公用事业、银行等板块不振。 | Wind热门概念指数 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | CRO | 炒股软件 | 电路板 | 高速铜连接 | 4.06% | 3.26% | 3.01% | 3.01% | | 消费电子代工 | 英伟达产业链 | HBM | Al手机 | 2.11% | 2.6 ...

Core Viewpoint - The approval of the raw material drug cytidine diphosphate choline by the National Medical Products Administration marks a significant milestone for the company, enhancing its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Xinxiang Pharmaceutical, received the "Approval Notification for Chemical Raw Material Drug Listing Application" for cytidine diphosphate choline [1] - This approval indicates that the product meets national drug review technical standards and has passed GMP compliance checks [1] Group 2: Product Significance - Cytidine diphosphate choline is commonly used as a neuroprotective agent and brain metabolism activator, with its core pharmacological action being the improvement of brain function and promotion of nerve repair [1] - The clinical application range includes patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases [1] Group 3: Market Impact - The approval will effectively broaden the company's product line and enhance its market competitiveness in the active pharmaceutical ingredient sector [1]

近日，拓新药业集团股份有限公司（以下简称"公司"）全资子公司新乡制 药股份有限公司（以下简称"新乡制药"）胞磷胆碱原料药收到国家药品监督管 理局签发的《化学原料药上市申请批准通知书》（受理号：CYHS2360697），并 在国家药品监督管理局药品审评中心官方网站公示,现将相关情况公告如下： 一、 原料药登记信息 通用名称：胞磷胆碱 英文名/拉丁名：Citicoline 证券代码：301089 证券简称：拓新药业 公告编号：2025-032 拓新药业集团股份有限公司 关于全资子公司胞磷胆碱原料药 获得上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 胞磷胆碱作为临床常用的神经保护剂与脑代谢激活剂，其核心药理作用在于 改善脑功能、促进神经修复，临床适用范围涵盖脑损伤、脑血管疾病、神经系统 退行性疾病等患者群体。该药品通过提高脑细胞能量代谢效率、稳定细胞膜结构、 1 加速受损神经组织修复等机制发挥作用，在脑卒中、脑外伤等疾病的辅助治疗中 具有重要临床价值。 化学原料药注册标准编号：YBY66352025 申请事项：境内生产化学原料药上市申请 ...

Core Viewpoint - The announcement details the completion of a share reduction plan by a significant shareholder of Tuoxin Pharmaceutical, indicating a decrease in the shareholding percentage of the controlling shareholder and its concerted parties, but clarifying that this will not impact the company's governance structure or control [1]. Group 1: Share Reduction Details - The concerted party, Yiwos Trading Co., Ltd., reduced its holdings by a total of 3,122,086 shares, representing 2.47% of the company's total share capital [1]. - The reduction occurred through two methods: 1,265,400 shares were sold via centralized bidding at an average price of 30.93 yuan per share from March 14 to May 19, and 1,856,686 shares were sold through block trading at an average price of 27.03 yuan per share from April 1 to June 6 [1][2]. - The overall average selling price for the shares reduced was 28.61 yuan per share, resulting in a total reduction amount of approximately 89.32 million yuan [1]. Group 2: Company Background and Financials - Tuoxin Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on October 27, 2021, with an initial public offering of 31.5 million shares at a price of 19.11 yuan per share [2]. - The total funds raised from the initial public offering amounted to 602 million yuan, with a net amount of 543 million yuan after deducting issuance costs, exceeding the original plan by 148 million yuan [3]. - The funds raised are intended for projects including the construction of nucleoside series specialty raw materials and pharmaceutical intermediates, the establishment of the Tuoxin Pharmaceutical Research Institute, and to supplement working capital [3].